Experienced in Fibrolamellar Carcinoma

Dr. Carolyn D. Britten

Oncology | Transplant Surgery | Hematology Oncology
171 Ashley Ave, 
Charleston, SC 
Experienced in Fibrolamellar Carcinoma
171 Ashley Ave, 
Charleston, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Carolyn Britten is an Oncologist and a Transplant Surgeon in Charleston, South Carolina. Dr. Britten is rated as an Experienced provider by MediFind in the treatment of Fibrolamellar Carcinoma. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Lung Adenocarcinoma.

Her clinical research consists of co-authoring 31 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Transplant Surgery
Hematology Oncology
Licenses
Transplant Surgery in CA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

171 Ashley Ave, Charleston, SC 29425

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib
A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib
Enrollment Status: Withdrawn
Publish Date: April 27, 2025
Intervention Type: Drug
Study Phase: Phase 2
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: March 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Clopidogrel, Acetylsalicylic Acid
Study Phase: Phase 1
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy
Enrollment Status: Terminated
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: OPC
Study Phase: Phase 1
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drugs: PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Study Phase: Phase 1/Phase 2
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
A Multicenter Study With an Open-label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the DNA-PK Inhibitor Peposertib (M3814) in Combination With Capecitabine and RT in Participants With Locally Advanced Rectal Cancer
Enrollment Status: Completed
Publish Date: March 21, 2023
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: June 28, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Nab-paclitaxel, Gemcitabine
Study Phase: Phase 1/Phase 2
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: March 09, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies
Enrollment Status: Completed
Publish Date: June 01, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: April 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 14 Less Clinical Trials

31 Total Publications

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.
Journal: American journal of clinical oncology
Published: July 18, 2022
Similar Doctors
Advanced in Fibrolamellar Carcinoma
Dr. Paul E. O'brien
Oncology | Hematology
Advanced in Fibrolamellar Carcinoma
Dr. Paul E. O'brien
Oncology | Hematology

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Paul O'brien is an Oncologist and a Hematologist in Charleston, South Carolina. Dr. O'brien is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Familial Pancreatic Cancer, Colorectal Cancer, Pancreatic Cancer, Endoscopy, and Gastric Bypass. Dr. O'brien is currently accepting new patients.

Experienced in Fibrolamellar Carcinoma
Dr. Douglas L. Michaelsen
Hematology Oncology | Hematology | Oncology
Experienced in Fibrolamellar Carcinoma
Dr. Douglas L. Michaelsen
Hematology Oncology | Hematology | Oncology

Bon Secours St Francis Xavier Hospital Inc

2910 Tricom St, 
N Charleston, SC 
 (14.9 miles away)
843-572-9211
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Douglas Michaelsen is a Hematologist Oncology specialist and a Hematologist in N Charleston, South Carolina. Dr. Michaelsen is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Myelodysplastic Syndrome (MDS), and Paget Disease of the Breast. Dr. Michaelsen is currently accepting new patients.

Experienced in Fibrolamellar Carcinoma
Dr. Steven I. Hanish
Transplant Surgery | General Surgery
Experienced in Fibrolamellar Carcinoma
Dr. Steven I. Hanish
Transplant Surgery | General Surgery

University Medical Associates Of The Medical University Of South Carol

171 Ashley Ave, 
Charleston, SC 
 (0.1 miles away)
843-792-1414
Languages Spoken:
English
See accepted insurances

Steven Hanish is a Transplant Surgeon and a General Surgeon in Charleston, South Carolina. Dr. Hanish is rated as a Distinguished provider by MediFind in the treatment of Fibrolamellar Carcinoma. His top areas of expertise are Liver Failure, Alcoholic Cirrhosis, Hepatitis, Liver Transplant, and Hepatectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Britten's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 27 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile